Tirzepatide
Tirzepatide is an active pharmaceutical ingredient developed by Eli Lilly that activates GIP and GLP-1 receptors. In the United States, it connects two major product records: Zepbound for obesity-related indications and Mounjaro for type 2 diabetes. Tirzepatide is not itself a brand, indication, dose, presentation, or market-availability claim.
The US ingredient record reviewed here is current to July 23, 2026. The current Zepbound label and current Mounjaro label should be checked before reusing product-specific indication, population, presentation, dose, or safety claims.
Reference record
Section titled “Reference record”| Field | Tirzepatide record |
|---|---|
| Entity type | Active pharmaceutical ingredient |
| Principal company | Eli Lilly |
| Mechanism class | GIP/GLP-1 receptor agonist |
| US obesity-market product | Zepbound |
| Adjacent US diabetes product | Mounjaro |
| US route in approved products | Subcutaneous injection |
| First US product approval | May 13, 2022, for Mounjaro |
| Major obesity-development program | SURMOUNT |
Ingredient, brand, and product are different records
Section titled “Ingredient, brand, and product are different records”Tirzepatide identifies the active ingredient. It does not identify which brand, indication, application, delivery presentation, dose, market, payer status, or supply record is being discussed.
| Record level | Tirzepatide example |
|---|---|
| Active ingredient | Tirzepatide |
| Obesity-market brand and product | Zepbound |
| Adjacent diabetes-market brand and product | Mounjaro |
| Mechanism grouping | GIP and GLP-1 receptor agonism |
| Clinical-development program | SURMOUNT for obesity-related development; SURPASS for type 2 diabetes development |
| Regulatory record | Product-, indication-, presentation-, date-, and jurisdiction-specific FDA action |
This separation prevents a common error: treating an ingredient name as if it automatically carried every indication or commercial attribute of every product containing it.
Product map
Section titled “Product map”| Product | US role | Ingredient relationship | Interpretation boundary |
|---|---|---|---|
| Zepbound | Adult long-term weight reduction and maintenance; moderate-to-severe obstructive sleep apnea in adults with obesity | Contains tirzepatide | Zepbound’s product label does not apply to Mounjaro or unbranded ingredient references |
| Mounjaro | Type 2 diabetes product | Contains tirzepatide | Mounjaro’s diabetes label is separate from Zepbound’s obesity-related label |
The FDA Mounjaro approval snapshot, FDA Zepbound approval notice, and current product labels support these distinctions.
Mechanism and formulation context
Section titled “Mechanism and formulation context”Tirzepatide is a GIP receptor and GLP-1 receptor agonist. Grouping it at the mechanism level helps connect the ingredient to incretin biology, Lilly’s broader cardiometabolic portfolio, and products with related targets.
Mechanism grouping is not a clinical-equivalence claim. Tirzepatide differs from single-receptor GLP-1 agonists and from investigational triple-receptor agonists, but receptor count alone does not determine comparative efficacy, safety, dose, indication, route, availability, or suitability.
The approved US tirzepatide products reviewed here are subcutaneous injections. Product presentations include pens and vials, with current device and package configurations described in the individual labels. An ingredient record should not flatten presentation-specific concentration, volume, dose, device, or administration fields into a single generic formulation.
Company and commercial relationships
Section titled “Company and commercial relationships”Eli Lilly is the originator and principal commercial company connected to tirzepatide. FDA records identify Lilly in the Mounjaro and Zepbound applications, while current labels identify the US marketer and product-specific packaging context.
The company relationship spans more than branding:
- discovery and clinical development of tirzepatide
- sponsorship of the SURPASS and SURMOUNT programs
- US regulatory applications for Mounjaro and Zepbound
- presentation and device expansion
- manufacturing-capacity investment
- commercial channels including selected Zepbound vial distribution through LillyDirect
These relationships should not be compressed into the statement that Lilly physically manufactures every presentation at one identifiable site. Application holder, labeler, marketer, active-ingredient producer, fill-finish operator, device supplier, packager, distributor, and dispensing pharmacy are distinct roles.
Clinical-development map
Section titled “Clinical-development map”Tirzepatide connects several clinical programs, populations, and research questions.
| Program or study family | Primary relationship | Ingredient interpretation |
|---|---|---|
| SURPASS | Type 2 diabetes development | Supports the ingredient’s Mounjaro development history |
| SURMOUNT | Obesity and weight-management development | Connects tirzepatide to Zepbound’s original obesity-product record |
| SURMOUNT-OSA | Obstructive-sleep-apnea studies in adults with obesity | Connects tirzepatide to Zepbound’s later OSA indication |
| SURMOUNT-5 | Head-to-head study with semaglutide | Comparative record that must retain design, population, dose, endpoint, duration, and analysis context |
| SURMOUNT-MMO | Morbidity and mortality outcomes research | Ongoing investigational evidence beyond current approved indications |
| SUMMIT | Heart-failure and obesity research | Clinical evidence context that does not by itself create a Zepbound heart-failure indication |
The SURMOUNT-1 record, SURMOUNT-5 record, and SURMOUNT-MMO record provide specific registry anchors. Trial outcomes should retain population, comparator, duration, endpoint definition, estimand, missing-data handling, and source context.
US regulatory history
Section titled “US regulatory history”Tirzepatide’s regulatory history is a sequence of product-specific actions.
| Date | Product event | Ingredient significance |
|---|---|---|
| May 13, 2022 | FDA approved Mounjaro for glycemic control in adults with type 2 diabetes | First US approval of a tirzepatide product |
| November 8, 2023 | FDA approved Zepbound for long-term weight reduction and maintenance in a defined adult population | Established the separate US obesity-product record |
| December 20, 2024 | FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity | Added a product-specific obesity-related indication |
| 2024–2026 | FDA cleared additional Zepbound and Mounjaro presentations through supplemental records | Expanded product delivery options without changing ingredient identity |
These events do not create a single universal “tirzepatide approval.” Each approval belongs to a named product, application, indication, population, presentation, jurisdiction, and date.
Safety and comparison boundaries
Section titled “Safety and comparison boundaries”The current Zepbound and Mounjaro labels contain product-specific boxed warnings, contraindications, warnings, precautions, adverse reactions, interactions, and use-in-population information. Ingredient-level summaries should link to those labels rather than substitute for them.
The Zepbound label states that coadministration with another tirzepatide-containing product or a GLP-1 receptor agonist is not recommended. That is a product-label limitation and should not be converted into generalized prescribing advice on an industry reference page.
What not to infer
Section titled “What not to infer”- Tirzepatide is not synonymous with Zepbound or Mounjaro.
- One tirzepatide product’s indication does not transfer to another product.
- Shared active ingredient does not establish interchangeable branding, dosing, presentation, device, coverage, price, supply, or market availability.
- GIP/GLP-1 receptor activity does not establish superiority over GLP-1, triple-receptor, amylin, or non-incretin products.
- A head-to-head trial result applies only within its studied population, design, comparator, doses, duration, endpoints, and analysis.
- Clinical study status is not regulatory approval.
- FDA approval does not establish insurance coverage, reimbursement, local inventory, affordability, or individual suitability.
- This ingredient record is not treatment, dosing, switching, or prescribing guidance.
Related records
Section titled “Related records”- Zepbound for the obesity-product, presentation, indication, and regulatory record
- Eli Lilly for company, pipeline, manufacturing, and commercial context
- Active ingredients for ingredient-level comparison
- GIP/GLP-1 receptor agonists for the mechanism and class record
- SURMOUNT for the obesity-development program
- Regulatory milestones for dated product-level actions
- Active ingredient vs brand vs product for the underlying identity distinction
- Dose, formulation, and route for presentation-level interpretation